Document is current
Any future updates will be listed below
-
Authors
Good, Zinaida
Spiegel, Jay Y. https://orcid.org/0000-0001-6491-0044
Sahaf, Bita
Malipatlolla, Meena B.
Ehlinger, Zach J.
Kurra, Sreevidya
Desai, Moksha H.
Reynolds, Warren D.
Wong Lin, Anita
Vandris, Panayiotis https://orcid.org/0000-0002-4917-9019
Wu, Fang
Prabhu, Snehit
Hamilton, Mark P.
Tamaresis, John S.
Hanson, Paul J.
Patel, Shabnum https://orcid.org/0000-0002-4782-9540
Feldman, Steven A.
Frank, Matthew J.
Baird, John H.
Muffly, Lori https://orcid.org/0000-0002-9887-6136
Claire, Gursharan K.
Craig, Juliana https://orcid.org/0000-0002-5644-2292
Kong, Katherine A.
Wagh, Dhananjay https://orcid.org/0000-0002-6937-003X
Coller, John
Bendall, Sean C. https://orcid.org/0000-0003-1341-2453
Tibshirani, Robert J.
Plevritis, Sylvia K.
Miklos, David B. https://orcid.org/0000-0003-0717-4305
Mackall, Crystal L. https://orcid.org/0000-0001-6323-4304
- License Information
-
More Information
Article History
Received: 3 May 2022
Accepted: 19 July 2022
First Online: 12 September 2022
Competing interests
: Z.G. is an inventor on two patent applications, holds equity in Boom Capital Ventures and is a consultant for Mubadala Ventures, GLG, AlphaSights and Atheneum Partners, all of which are related to the cancer immunotherapy space. S.A.F. holds patents in the field of cell and gene therapy and serves on the scientific advisory boards for Alaunos Therapeutics and FreshWind Biotechnologies. D.B.M. holds a patent with Pharmacyclics supporting ibrutinib for chronic graft-versus-host disease and receives consulting or research fees or serves as an advisor for Pharmacyclics, Kite Pharma, Adaptive Biotechnologies, Novartis, Juno Therapeutics, Celgene, Janssen Pharmaceuticals, Roche, Genentech, Precision Bioscience, Allogene and Miltenyi Biotec. C.L.M. is an inventor on numerous CAR T cell immunotherapy patent applications and received royalties for the CD22-CAR from the National Institutes of Health after licensure to Opus Bio and Juno Therapeutics. C.L.M. is a cofounder of Lyell Immunopharma, Syncopation Life Sciences and Link Cell Therapies, which are developing CAR-based therapies, and consults for Lyell, Syncopation, Link, Mammoth, Ensoma, NeoImmune Tech, Apricity, Nektar, Immatics, GlaxoSmithKline and Bristol Myers Squibb. None of the above interests is related to the research described in this manuscript. All other authors declare no competing interests.
